Top

Published in:

01-10-2017 | Original Article

Comparison of Core Needle Biopsy and Excision Specimens for the Accurate Evaluation of Breast Cancer Molecular Markers: a Report of 1003 Cases

Authors: Jie Chen, Zu Wang, Qing Lv, Zhenggui Du, Qiuwen Tan, Di Zhang, Bingjun Xiong, Helin Zeng, Juxiang Gou

Published in: Pathology & Oncology Research | Issue 4/2017

Abstract

In this study, we compared the accuracy of marker evaluation in core needle biopsy (CNB) specimens versus excision specimens (ESs) from breast cancer patients. This retrospective study used data collected from the breast cancer database at the West China Hospital, China. Immunohistochemistry (IHC) results from CNB specimens and ESs were compared, using estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 as markers. Molecular subtyping and endocrine therapy usage correlations based on CNB samples and ESs were evaluated. The results obtained from CNB samples and ESs exhibited substantial agreement for the detection of ER (κ = 0.522), PR (κ = 0.441), and HER2 (κ = 0.451), and also influenced endocrine therapy usage. Fair and poor correlations were observed for Ki-67 staining and molecular subtyping (κ = 0.195), respectively. This disagreement might be attributable to a combination of heterogeneity and large tumor size. This study indicates that the discordance rate in molecular marker staining between CNB specimens and ESs is significant enough that results obtained with CNB specimens should be used cautiously or verified using ESs.

NCCN Clinical Practice Guidelines in Oncology: Breast cancer (2015) www.NCCN.com.

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumors. Nature 406:747–752CrossRefPubMed

Gonçalves AV, Thuler LC, Kestelman FP, Carmo PA, Lima CF, Cipolotti R (2011) Underestimation of malignancy of core needle biopsy for nonpalpable breast lesions. Rev Bras Ginecol Obstet 33:123–131PubMed

Dekker TJ, Smit VT, Hooijer GK, Van de Vijver MJ, Mesker WE, Tollenaar RA, Nortier JW, Kroep JR (2013) Reliability of core needle biopsy for determining ER and HER2 status in breast cancer. Ann Oncol 24:931–937. doi:10.1093/annonc/mds599 CrossRefPubMed

Chen X, Yuan Y, Gu Z, Shen K (2012) Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis. Breast Cancer Res Treat 134:957–967. doi:10.1007/s10549-012-1990-z CrossRefPubMed

Goldhirsch A, Wood WC, Coates A, Gelber RD, Thürlimann H, Senn HJ, Panel member (2011) Subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736–1747CrossRefPubMedPubMedCentral

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr (2007) American Society of Clinical Oncology: American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287–5312CrossRefPubMed

Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S (2010) American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract 6:195–197. doi:10.1200/JOP.777003 CrossRefPubMedPubMedCentral

Usami S, Moriya T, Amari M, Suzuki A, Ishida T, Sasano H, Ohuchi N (2007) Reliability of prognostic factors in breast carcinoma determined by core needle biopsy. Jpn J Clin Oncol 37:250–255. doi:10.1093/jjco/hym021 CrossRefPubMed

10.

Ricci MD, Calvano Filho CM, Oliveira Filho HR, Filassi JR, Pinotti JA, Baracat EC (2012) Analysis of the concordance rates between core needle biopsy and surgical excision in patients with breast cancer. Rev Assoc Med Bras 58:532–536. doi:10.1016/S0104-4230(12)70245-2 CrossRefPubMed

11.

Petrau C, Clatot F, Cornic M, Berghian A, Veresezan L, Callonnec F, Baron M, Veyret C, Laberge S, Thery JC, Picquenot JM (2015) Reliability of prognostic and predictive factors evaluated by needle Core biopsies of large breast invasive tumors. Am J Clin Pathol 144:555–562. doi:10.1309/AJCP9KFVM2GZMNDV CrossRefPubMed

12.

Litherland JC, Evans AJ, Wilson AR, Kollias J, Pinder SE, Elston CW, Ellis IO, Yeoman LJ (1996) The impact of core-biopsy on pre-operative diagnosis rate of screen detected breast cancers. Clin Radiol 51:562–565. doi:10.1016/S0009-9260(96)80136-X CrossRefPubMed

13.

Youk JH, Kim EK, Kim MJ, Oh KK (2008) Sonographically guided 14-gauge core needle biopsy of breast masses: a review of 2,420 cases with long-term-follow-up. AJR Am J Roentgenol 190:202–207. doi:10.2214/AJR.07.2419 CrossRefPubMed

14.

Collins LC, Connolly JL, Page DL, Goulart RA, Pisano ED, Fajardo LL, Berg WA, Caudry DJ, McNeil BJ, Schnitt SJ (2004) Diagnostic agreement in the evaluation of image-guided breast core needle biopsies: results from a randomized clinical trial. Am J Surg Pathol 28:126–123. doi:10.1097/00000478-200401000-00015 CrossRefPubMed

15.

Crowe JP Jr, Rim A, Patrick RJ, Rybicki LA, Grundfest-Broniatowski SF, Kim JA, Lee KB (2003) Does core needle breast biopsy accurately reflect breast pathology? Surgery 134:523–526CrossRefPubMed

16.

Crowe JP Jr, Patrick RJ, Rybicki LA, Grundfest SF, Kim JA, Lee KB, Rim A (2003) Does ultrasound core breast biopsy predict histologic finding on excisional biopsy? Am J Surg 186:397–399CrossRefPubMed

17.

Li S, Yang X, Zhang Y, Fan L, Zhang F, Chen L, Zhou Y, Chen X, Jiang J (2012) Assessment accuracy of core needle biopsy for hormone receptors in breast cancer: a meta-analysis. Breast Cancer Res Treat 135:325–334. doi:10.1007/s10549-012-2063-z CrossRefPubMed

18.

Sutela A, Vanninen R, Sudah M, Berg M, Kiviniemi V, Rummukainen J, Kataja V, Kärjä V (2008) Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer. Acta Oncol 47(1):38–46. doi:10.1080/02841860701441822 CrossRefPubMed

19.

Seferina SC, Nap M, van den Berkmortel F, Wals J, Voogd AC, Tjan-Heijnen VC (2013) Reliability of receptor assessment on core needle biopsy in breast cancer patients. Tumour Biol 34:987–994. doi:10.1007/s13277-012-0635-5 CrossRefPubMed

20.

Lorgis V, Algros MP, Villanueva C, Chaigneau L, Thierry-Vuillemin A, Nguyen T, Demarchi M, Bazan F, Sautiere JL, Maisonnette-Lescot Y, Ringenbach F, Bontemps P, Pivot X (2011) Discordance in early breast cancer for tumour grade, estrogen receptor, progesterone receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour. Breast 20:284–287. doi:10.1016/j.breast.2010.12.007 CrossRefPubMed

21.

Munch-Petersen HD, Rasmussen BB, Balslev E (2014) Reliability of histological malignancy grade, ER and HER2 status on core needle biopsy vs surgical specimen in breast cancer. APMIS 122:750–754. doi:10.1111/apm.12213 CrossRefPubMed

22.

Chen X, Zhu S, Fei X, Garfield DH, Wu J, Huang O, Li Y, Zhu L, He J, Chen W, Jin X, Shen K (2015) Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients. BMC Cancer 15:822. doi:10.1186/s12885-015-1853-1 CrossRefPubMedPubMedCentral

23.

Greer LT, Rosman M, Mylander WC, Hooke J, Kovatich A, Sawyer K, Buras RR, Shriver CD, Tafra L (2013) Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens? J Am Coll Surg 216:239–251. doi:10.1016/j.jamcollsurg.2012.09.007 CrossRefPubMed

24.

Ough M, Velasco J, Hieken TJ (2011) A comparative analysis of core needle biopsy and final excision for breast cancer: histology and marker expression. Am J Surg 201:692–694. doi:10.1016/j.amjsurg.2010.02.015 CrossRefPubMed

25.

Zhang Z, Yuan P, Guo H, Zhao L, Ying J, Wang M, Zhao H, Pan Q, Xu B (2015) Assessment of hormone receptor and human epidermal growth factor receptor 2 status in breast carcinoma using thin-prep cytology fine needle aspiration cytology FISH experience from China. Medicine (Baltimore) 94:e981. doi:10.1097/MD.0000000000000981 CrossRef

26.

Chen X, Sun L, Mao Y, Zhu S, Wu J, Huang O, Li Y, Chen W, Wang J, Yuan Y, Fei X, Jin X, Shen K (2013) Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer. BMC Cancer 13:390. doi:10.1186/1471-2407-13-390 CrossRefPubMedPubMedCentral

27.

Uy GB, Laudico AV, Carnate JM Jr, Lim FG, Fernandez AM, Rivera RR, Mapua CA, Love RR (2010) Breast cancer hormone receptor assay results of core needle biopsy and modified radical mastectomy specimens from the same patients. Clin Breast Cancer 10:154–159. doi:10.3816/CBC.2010.n.021 CrossRefPubMedPubMedCentral

28.

VandenBussche CJ, Cimino-Mathews A, Park BH, Emens LA, Tsangaris TN, Argani P (2015) Reflex estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 analysis of breast cancers in needle core biopsy specimens dramatically increases health care costs. Am J Surg Pathol 39:939–947. doi:10.1097/PAS.0000000000000424 CrossRefPubMed

29.

Douglas-Jones AG, Collett N, Morgan JM, Jasani B (2001) Comparison of core estrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma. J Clin Pathol 54:951–955CrossRefPubMedPubMedCentral

30.

Tamaki K, Sasano H, Ishida T, Miyashita M, Takeda M, Amari M, Tamaki N, Ohuchi N (2010) Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgRand HER2 status of breast cancer patients. Cancer Sci 101:2074–2079. doi:10.1111/j.1349-7006.2010.01630.x CrossRefPubMed

31.

Melotti MK, Berg WA (2000) Core needle breast biopsy in patients undergoing anticoagulation therapy: preliminary results. AJR Am J Roentgenol 174:245–249. doi:10.2214/ajr.174.1.1740245 CrossRefPubMed

32.

Ozdemir A, Voyvoda NK, Gultekin S, Tuncbilek I, Dursun A, Yamac D (2007) Can core biopsy be used instead of surgical biopsy in the diagnosis and prognostic factor analysis of breast carcinoma? Clin Breast Cancer 7:791–795. doi:10.3816/CBC.2007.n.041 CrossRefPubMed

33.

Hoda SA, Harigopal M, Harris GC, Pinder SE, Lee AH, Ellis IO (2003) Expert opinion: reporting needle core biopsies of breast carcinomas. Histopathology 43:84–90CrossRefPubMed

Title: Comparison of Core Needle Biopsy and Excision Specimens for the Accurate Evaluation of Breast Cancer Molecular Markers: a Report of 1003 Cases
Authors: Jie Chen
Zu Wang
Qing Lv
Zhenggui Du
Qiuwen Tan
Di Zhang
Bingjun Xiong
Helin Zeng
Juxiang Gou
Publication date: 01-10-2017
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 4/2017
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-017-0187-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2017

Prognostic Implications of miR-302a/b/c/d in Human Gastric Cancer

Anastomosing Hemangioma of the Ovary: A Clinicopathological Study of Six Cases with Stromal Luteinization

Transcriptional Regulatory Network Analysis for Gastric Cancer Based on mRNA Microarray

Unusual Signal Patterns of Break-apart FISH Probes Used in the Diagnosis of Soft Tissue Sarcomas

Identification of Changes in the Human Papilloma Virus 16 (HPV16) Genome During Early Dissemination of Cervical Cancer Cells May Complement Histological Diagnosis of Lymph Node Metastasis

Entangling Relation of Micro RNA-let7, miRNA-200 and miRNA-125 with Various Cancers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer